Factors associated of long-term retention rate of Janus kinase inhibitors in a multi-failure rheumatoid arthritis population

CONCLUSIONS: In conclusion, our study supports the clinical effectiveness of JAKi in RA, even in the multi-failure subgroup of patients, where the risk/benefit ratio overcomes the safety risk. The presence of ACPA and the concurrent use of + cs-DMARD may increase the survival on JAKi in the long term.PMID:38530664 | DOI:10.55563/clinexprheumatol/za0hpu

Source: Clinical and Experimental Rheumatology - March 26, 2024 Category: Rheumatology Authors: Marco Sebastiani Alen Zabotti Bruno Biasi Sofia Cacioppo Gilda Sandri Ivan Giovannini Andreina Manfredi Luca Quartuccio Source Type: research